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Kidney International (2018) 94, 1141–1150T he complement system consists of 3 activation path-ways, classical (CP), lectin (LP), and alternative (AP),which converge at the level of C3 activation, proceeding
to C5 cleavage and initiating the terminal pathway C5–C9
activation. Both the CP and LP have pattern recognition
molecules (PRM), such as C1q and MBL, which in combi-
nation with the associated proteases initiate the complement
cascade.1 AP has an important role in augmenting CP and LP;
once C3 is activated, the AP ampliﬁcation loop enhances the
complement cascade activation.2,3 In addition, there is a
constant low-level auto-activation of C3 (tick-over), which
allows C3b formation on surfaces of pathogens and injured
host cells.1,4 The membrane-bound C3b associates with factor
B, forming a short-lived AP C3 convertase C3bBb, which
properdin binding stabilizes signiﬁcantly, and making pro-
perdin the only positive regulator of complement.5–8
Recent in vitro studies have shown that properdin may
exhibit PRM activity. Studies have shown targeted
complement-ﬁxing activity on certain ligands such as lipo-
polysaccharides (LPS),9 oxidized LDL,10 and myeloperox-
idase.11 Similar results have been demonstrated with
apoptotic and necrotic cells, and heparan sulfates expressed at
the surface of renal epithelial cells.12–16 In this model pro-
perdin attaches to speciﬁc ligands and forms stable C3bBbP
convertase, possibly overcoming the local threshold for C5
convertase (C3bBbC3b) formation.8,9,12 However, it is not yet
clear how properdin could act as a PRM, as it lacks known
recognition domains.17
AP and properdin have been shown to contribute to
arthritis, abdominal aortic aneurysm, and renal ischemia
reperfusion injury (I/RI). However, these studies have not
been able to differentiate whether the deposition of properdin
in tissues takes place via membrane-bound C3b or through
epitopes present in the injured tissues.18–21 To study the
sequence of properdin binding in vivo, we established an
acute model of anti–glomerular basement membrane (GBM)
disease in wild-type (WT), C3 knockout (KO), and properdin
KO mice. Recent studies on anti-GBM disease have shown
that properdin and other AP components are prominently
present in anti-GBM–affected glomeruli in humans and that
AP contributes to the injury in mice,22–24 making the model
attractive for studying properdin.1141
bas i c re sea r ch J O’Flynn et al.: Properdin binding in vivo can occur independently of C3RESULTS
Characterization of acute complement activation after anti-
GBM antibody initiation
Acute complement activation was evaluated with comparison
of mouse plasma before and 2 hours post-administration of
anti-GBM antibody, showing signiﬁcantly increased C3b/C3c/
iC3b in WT mice (3.6-fold), which was not seen following
administration of control IgG or in properdin-KO (fP KO)
mice (Figure 1a). Moreover, basal levels of C3 activation
fragments was 2-fold lower in fP KO mice compared with the
WT mice.
The novel mouse properdin enzyme-linked immunosor-
bent assay (ELISA) has a linear detection range with recom-
binant mouse properdin (Figure 1b) with no detectable
properdin in fP KO mouse serum (Figure 1c). No changes in
circulating properdin were found 2 hours after injection of
WT mice with anti-GBM or control antibody (Figure 1c).
Functional ELISAs established intact serum complement
in WTmice and reduced AP activity in the fP KO mice. Two
hours after anti-GBM antibody injection, prominent con-
sumption of CP (Figure 1d) and AP (Figure 1e) was seen,
whereas ﬁndings for LP consumption were inconclusive
(Figure 1e). No consistent complement consumption was
observed with control antibody–injected mice. In properdin
KO mice anti-GBM antibody injection did not result in
signiﬁcant CP or LP pathway consumption (Figure 1f).
Together these results show prominent complementFigure 1 | Analysis of systemic complement. (a) Acute complement a
paired pre- and post-injection samples from anti–glomerular basement
knockout (fP KO) mice and control polyclonal antibody (pAb)-treated W
(ELISA) performance was assessed with reciprocal dilutions of recombin
properdin levels were assessed 2 hours after induction of the model wi
injected WT mice. (d) Serum classical (CP), (e) lectin (LP), and (f) alternati
Two-way analysis of variance (ANOVA) was used to determine change spe
to determine speciﬁcity of change between control and anti-GBM antib
***P < 0.001. aGBM, anti-GBM antibody; NS, not signiﬁcant; Rb IgG, rab
1142activation in this anti-GBM model, with partial dependence
on properdin.
Time course histological analysis of complement activation in
glomeruli
The kinetics of renal complement activation following anti-
GBM antibody injection were evaluated in groups of WT
mice killed at different time points. The anti-GBM rabbit IgG
(Rb IgG) was clearly present in glomerular vasculature from 2
to 72 hours (Figure 2). The C1q staining was performed as a
marker of CP involvement, showing an acute and unchanged
staining pattern from 2 to 72 hours, closely resembling that of
Rb IgG (Figure 2). The C3 deposition was present in
glomeruli at 2 hours and increased until 72 hours. The C3
deposition closely resembled the pattern of rabbit IgG until 48
hours, after which a focal staining pattern became more
apparent (Fig 2). Properdin deposition was present at 2 hours,
with clear increase from 24 hours onwards. Interestingly,
properdin (fP) staining did not exhibit the linear pattern
found with IgG and C3 (Figure 2). The staining for both C6
and C9 exhibited late kinetics, emerging only after 24 hours
and becoming most prominent at 48 hours (Figure 2). In all
cases speciﬁcity of the staining was conﬁrmed with isotype
and biological positive and negative controls (Supplementary
Figure S1). We did not observe gender-speciﬁc differences in
staining pattern or intensity in any of the studied complement
factors (data not shown).ctivation was determined with plasma C3b/C3c/iC3b at 2 hours with
membrane (GBM) antibody–treated wild-type (WT) and properdin
T mice. (b) Properdin sandwich enzyme-linked immunosorbent assay
ant mouse properdin with 4-fold steps from 1000 ng/ml. (c) Serum
th anti-GBM antibody in WT and fP KO mice, and with control pAb-
ve (AP) pathway activities were determined with functional C3 ELISAs.
ciﬁcity in pre- and post-injection analysis, and 1-way ANOVA was used
odies. Error bars represent SD of duplicate measurements. *P < 0.05,
bit anti-GBM IgG.
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Figure 2 | Time-course analysis of glomerular activation of complement. Analysis was performed with kidneys harvested from wild-type
C57bl/6 mice killed 2 to 72 hours (h) after administration of anti–glomerular basement membrane (GBM) IgG. Deposition of rabbit anti-GBM IgG
(Rb IgG) and mouse C1q (green) were detected with Alexa-488 secondary antibody. C3 deposition (red) was detected with Alexa-568–labeled
secondary antibody. Mouse properdin, C6, and C9 deposition (green) was detected with HRP-labeled secondary antibody and tyramide-FITC
ampliﬁcation. Images were acquired at 40 original magniﬁcation, 4 mice (2 female and 2 male) per group were analyzed, and the repre-
sentative glomerulus was chosen from images acquired from 4 different animals. To optimize viewing of this image, please see the online
version of this article at www.kidney-international.org.
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colocalization
The rapid deposition of C3 in the glomerulus, combined with
the systemic consumption of CP and linear deposition of both
Rb IgG and C1q, suggested an IgG- and CP-mediated acti-
vation mechanism. To verify this, we assessed glomerular
colocalization of Rb IgG and C3 with anti-GBM antibody–
injected WT mice. The time-course histology showed that
the deposition of C3 closely resembles both rabbit IgG and
C1q staining in the glomerular endothelium at 2 to 6 hours,Kidney International (2018) 94, 1141–1150with a clearly deﬁned vascular loop structure. From 48 hours
onwards, the C3 deposits lining the vascular endothelium
become more prominent, and signiﬁcant C3 staining is pre-
sent in the lumen independent from rabbit IgG deposits
(Figure 3a). With the same mice, we found clear colocaliza-
tion of properdin and C3 throughout the observation period,
suggestive of AP-mediated C3 activation (Figure 3b). How-
ever, the single deposits of both C3 and properdin were also
observed, especially at 48 to 72 hours, when properdin
staining was most prominent (Figure 3b).1143
Figure 3 | Time-course colocalization of rabbit anti–glomerular basement membrane (GBM) IgG with mouse C3, and mouse C3 with
properdin (fP). Analysis was performed with kidneys harvested from wild-type C57bl/6 mice killed 2 to 72 hours (h) after administration of anti-
GBM IgG. (a) Anti-GBM rabbit IgG (green) was detected with Alexa-488–labeled secondary antibody and C3 (red) with Alexa-568–labeled
secondary antibody, and nuclei (blue) were stained with Hoechst. (b) Mouse properdin (green) was detected with HRP-labeled secondary
antibody and tyramide FITC ampliﬁcation, and C3 (red) with PE-labeled secondary antibody. Images were acquired at 40 original magniﬁ-
cation, 4 mice (2 female and 2 male) per group were analyzed, and the representative glomerulus was chosen from images acquired from 4
different animals. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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involvement
Properdin deposition in C3-KO mice was demonstrated at
various time points (2, 24, and 72 hours) following anti-GBM
antibody treatment (Figure 4a). Colocalization of rabbit IgG
with properdin was only incidental, and properdin exhibited
strong single staining in both WT and C3 KO mice, with no
evident staining in fP KO mice (Figure 4b). To investigate cell
death, we performed terminal deoxynucleotidyl transferase
dUTP nick-end labeling (TUNEL) staining in 72-hour bi-
opsies (Figure 4c). TUNEL assay positivity was observed in
glomeruli staining positive for rabbit IgG, C3, and properdin.
However, when looking in detail, especially for C3 and pro-
perdin, only a minor fraction showed colocalization
(Figure 4c). Analysis of TUNEL and properdin staining in C3
KO mice showed close but nonoverlapping colocalization
within glomeruli at 72 hours, and properdin staining was
more abundant compared with TUNEL staining (Figure 4d).
Glomerular injury and proteinuria are not prevented in C3
and properdin KO mice
Next, we evaluated the impact of properdin KO on the anti-
GBM antibody–induced renal injury using urine albumin-
creatinine ratio (UACR) as a functional read-out (Figure 5).
The injection of anti-GBM antibody in WT C57bl/6 resulted
in severe albuminuria in 24-hour urine collected between 72
and 96 hours. The UACR in WTmice was signiﬁcantly higher
in anti-GBM antibody–injected mice compared with control
antibody–injected mice (60,761  30,011 mg/g and 1205 
282 mg/g, respectively). Compared with WT mice, the pro-
perdin KO and C3 KO mice showed a 36% to 40% lower level
of albuminuria (UACR of 36,420  16,994 mg/g and
40,373  18247 mg/g, respectively). However, statistical1144difference was not reached. Female WT and C3 KO mice
exhibited a higher degree of renal injury than did male mice.
In properdin KO mice no gender differences were observed
(Supplementary Table S1).
Neutrophil activation and inﬂammation after administration
of anti-GBM antibody
Neutrophils have been shown to contribute to renal injury in
experimental models of anti-GBM disease.24 Time-course
analysis of neutrophils using a GR1 staining showed that
inﬁltration within the glomeruli was biphasic, being most
prominent at 2 hours, returning to low levels at 24 to 48
hours, and increasing at 72 hours (Figure 6a). Acute inﬁl-
tration and activation of neutrophils was supported by a
transient 3-fold increase in serum myeloperxodase (MPO) at
2 to 6 hours (Figure 6b), which was followed with serum
amyloid protein (SAP) peaking at 24 hours and remaining
elevated until 72 hours (Figure 6c). Serum properdin showed
a gradual increase from baseline, which reached signiﬁcance
at 48 hours (Figure 6d).
Dependence of neutrophil inﬁltration on properdin
Complement anaphylatoxins C3a and C5a are potent che-
moattractants for inﬂammatory cells. Additionally, neutro-
phils contribute to the systemic properdin pool and can
secrete it locally.25,26 There was no clear colocalization with
properdin and GR1-positive neutrophils in the affected
glomeruli at 2 hours, and neither properdin nor neutrophils
were present in control antibody–treated mice (Figure 7a).
Furthermore, the degree of neutrophil inﬁltration was not
decreased in properdin KO mice (Figure 7b), suggesting that
in this model properdin-regulated activation of complement
does not contribute to recruitment of neutrophils.Kidney International (2018) 94, 1141–1150
Figure 4 | Characterization of properdin binding to injured glomeruli. (a) Time course of properdin (fP) deposition (red) in C3 knockout (KO)
mice treated with rabbit anti-GBM at 2, 24, and 72 hours (h) was detected with PE-labeled secondary antibody and counterstained with
Hoechst. (b) Localization of fP (green) stained with tyramide-FITC ampliﬁcation in relation to disease-inducing rabbit IgG (red) stained with
PE-labeled secondary antibody in wild-type (WT), C3 KO, and fP KO mice at 72 hours after anti-GBM antibody administration. (c) Colocalization
of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)–stained cells (green) with IgG, C3, and fP deposition detected with
PE-labeled secondary antibody (red) in WT mice at 72 hours. Cells are stained with Hoechst (blue). (d) Colocalization of fP with TUNEL-positive
cells at 72 hours in C3 KO mice treated with anti-GBM IgG. Arrows indicate TUNEL-positive cells and their location in the overlay images. To
optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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Recent studies have established that properdin has differing
roles in disease pathologies, with a contributing role in
experimental models of renal IRI and possibly arthritis and a
protective role in C3 glomerulopathy and sepsis.18,20,27,28 The
role of properdin as a positive regulator of AP is clear.
However, the possible PRM role remains unsolved. Recent
in vitro studies show that properdin has PRM activity and can
act as a focus point of local C3b deposition on several li-
gands.8,9,13,15,29 Conversely, in other cases properdin has been
shown to act only as a positive regulator, requiring preceding
C3b deposition to bind.30,31 To better understand the
mechanism of properdin binding and function in vivo, weKidney International (2018) 94, 1141–1150explored an experimental model of anti-GBM disease in WT,
properdin KO, and C3 KO mice.
Our model exhibited typical characteristics of an experi-
mental anti-GBMdisease, which include systemic complement
consumption, activation of AP and CP pathways, deposition of
complement factors in the glomeruli, neutrophil activation,
inﬂammation, and severe renal injury.23,24,32–34 Acute com-
plement activation was veriﬁed with plasma C3b/C3c/iC3b
fragments at 2 hours, which also revealed the impact of pro-
perdin as a positive regulator of AP because properdin KOmice
had a lower basal level of C3 activation fragments and less
prominent generation of C3 fragments. Furthermore, we
observed acute consumption of CP and AP, which was not1145
Figure 5 | Anti–glomerular basement membrane (GBM) disease–
induced proteinuria. Anti-GBM disease was induced with injection of
0.5 mg of rabbit anti-GBM IgG in wild-type (WT) C57bl/6 mice (n¼ 10),
properdin (fP) knockout (KO) mice (n¼ 8), and C3 KOmice (n¼ 9). The
control group WT C57bl/6 mice were injected with 0.5 mg of control
rabbit IgG (Ctrl IgGWT; n¼ 5). The sex of eachmouse is indicated in the
ﬁgure by either solid (male) or outlined (female) symbols. Twenty-four-
hour urine was collected from each mouse in metabolic cages at 72 to
96 hours for quantiﬁcation of urinary albumin-to-creatinine ratio.
Nonparametric 1-way analysis of variance with Dunn’s multiple com-
parison test was used to determine statistical signiﬁcance. Error bars
indicate SD. **P < 0.01. NS, not signiﬁcant.
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properdin and APampliﬁcation loop.5 Interestingly, we did not
observe serum properdin consumption in WT mice.
Conversely, the levels increased in tandemwith SAP, suggesting
that systemic inﬂammation may affect the secretion of pro-
perdin to circulation from activated inﬂammatory cells.25,35,36
It must be noted that the range of mouse properdin seemed
high compared with concentrations in human serum. Thismay
be due to the use of recombinant mouse properdin as a stan-
dard that may not have the same distribution of properdin
isoforms as is found in vivo.37
Time-course immunohistochemistry revealed an acute
C1q, C3, and properdin deposition in line with serum de-
terminations, suggesting CP- and AP-mediated complement
activation. However, C6 and C9 deposition became evident
only after 24 hours and continued to intensify from 48 to 72
hours, coinciding with increased C3 and properdin deposi-
tion. Together, these results suggest that in this model of anti-
GBM disease, the complement-mediated injury may be
attenuated until 48 to 72 hours. Further analysis of C3
colocalization conﬁrmed that initial complement activation is
most likely CP dependent and is present along the vascular
endothelium. However, after 48 hours the C3 staining
intensiﬁed and colocalized more with properdin, suggesting
AP and properdin involvement in complement activation. We
demonstrated that properdin deposition was present in
glomeruli of anti-GBM–injected C3 KO mice. We showed
some colocalization of properdin with TUNEL-positive cells,
potentially conﬁrming interaction with apoptotic cells.12,381146However, a large part of the properdin was independent of
TUNEL, thereby indicating the presence of other, yet
unknown ligands.
Properdin KO and C3 KO resulted in reduced proteinuria
compared with the WTmice; however, this protection was not
statistically signiﬁcant. This is in contrast to previous studies
with a 2-step model, which established involvement of both
complement and neutrophils in the experimental renal injury
in male mice.24 Although small group size did not allow for
proper statistical analysis, female mice seemed to exhibit
markedly higher proteinuria in WT and C3 KO mice in this
model. We did not observe differences in complement stains
between female and male mice, including C6 and C9. We have
recently shown that female C57bl/6 mice have signiﬁcantly
reduced terminal complement pathway functionality.39 In
light of our results here, we can conclude that this residual
complement activity results in prominent complement
deposition in vivo when the injury is localized, such as in the
glomeruli. Our results show an acute and transient inﬁltration
of neutrophils, with simultaneous increase of serum MPO
and SAP that precedes the full complement activation.
Furthermore, properdin KO did not impact neutrophil inﬁl-
tration, and no colocalization between neutrophils and pro-
perdin was observed. Together our results show that in this
model the initial CP- and AP-mediated C3 activation and
anti-GBM IgG are sufﬁcient to recruit neutrophils to the
glomeruli together with the rabbit IgG Fc receptor. Our re-
sults show only limited amelioration of renal injury using C3
KO mice, suggesting that the neutrophils are the likely driver
of the acute injury, and that the full complement activation
dependent on CP, AP, and properdin is attenuated and may
become a contributing factor later.24,40
Taken together, our results show that properdin is present
in injured glomeruli in vivo, independent of C3 involvement.
The mechanism and putative ligand facilitating the deposition
remains unclear, as only incidental colocalization was found
with C3, TUNEL-positive cells, neutrophils, and Igs. Further
studies should aim to identify whether this ﬁnding is a result
of speciﬁc epitopes or passive entrapment within the injured
glomeruli, and whether deposition of properdin may direct
further C3 activation in vivo. These ﬁndings are interesting for
various AP- and complement-mediated diseases. The ability
of properdin to interact independent of C3 in vivo expands its
possible roles in diseases and injuries. In particular, the role of
properdin in removal of apoptotic material12,16 and in
neutrophil-mediated diseases29,41–43 can be expanded further
with future in vivo studies using the methods, animals, and
reagents described here.METHODS
Study animals
C57BL/6 WT mice were purchased from Charles River Laboratories
(Wilmington, MA). C3 KO mice were a kind gift from Mike Carroll
(Harvard Medical School, Boston, MA), and properdin KO mice
were maintained by Cordula Stover (University of Leicester,
Leicester, UK).28 All experiments were approved by the LeidenKidney International (2018) 94, 1141–1150
Figure 6 | Analysis of neutrophil activation in a 1-step model of anti–glomerular basement membrane (GBM) disease. (a) Wild-type (WT)
mice were injected with anti-GBM IgG, and tissues were collected at different time points for staining of inﬁltrating neutrophils (red) with
Alexa-568–labeled secondary antibody and rat anti-mouse GR1, and overlaid with Hoechst nuclear stain (blue). Activation of neutrophils was
further analyzed with (b) serum myeloperxodase (MPO) measurement, and the impact on general inﬂammation with (c) serum amyloid protein
(SAP). (d) Finally, the impact of anti-GBM IgG to complement was assessed with time-course determination of serum properdin. All
measurements were done in at least duplicate, and statistical signiﬁcance was determined with 1-way analysis of variance. *P < 0.05, **P< 0.01.
To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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institutional and national guidelines.
Induction of glomerulonephritis
Rabbit anti-rat GBM IgG, cross-reacting with mouse GBM, was
prepared in house as previously described,44 and preparation and
cross-reactivity were conﬁrmed in pilot experiments with anti-GBM
and control antibodies injected into WT C57BL/6 mice. For the
model, both male and female age-matched (range: 7–10 weeks old)
mice (C57BL/6 WT, C3-KO, and properdin KO mice) were used. At
day 0, the mice were injected i.v. with rabbit anti-GBM or control
rabbit IgG (0.5 mg in 200 ml physiological saline).
Acute anti-GBM disease was evaluated at 2 hours after injection.
WTmice were injected with anti-GBM or control antibody, whereas
properdin KO mice were injected only with anti-GBM antibody. For
complement determinations, ethylenediamine tetra-acetic acid
plasma was collected by tail cuts from each mouse before and 2
hours after injection without anesthesia. Serum was collected after
CO2 killing via heart puncture. All blood samples were placed
directly on ice and prepared as plasma or serum as described
previously.45
The impact of C3 and properdin deﬁciency was investigated by
injecting either anti-GBM or control IgG (0.5 mg) in WT, C3 KO,
and properdin KO mice. The severity of renal injury was evaluated by
24-hour urine collection and proteinuria analysis from anti-GBM
antibody–injected WT (n ¼ 10), properdin-KO (n ¼ 8), and C3
KO (n ¼ 9) mice and WT mice injected with control antibody
(n ¼ 5). For urine collection mice were placed in metabolic cages 72Kidney International (2018) 94, 1141–1150hours after anti-GBM antibody administration with free access to
food and water. The collected urine was centrifuged, aliquoted, and
stored at –20C.
The kinetics of complement and neutrophil activation were
studied with groups of WTmice killed at 2 to 72 hours after injection
of anti-GBM IgG. Additional kidneys were collected at 2 hours from
properdin KO mice, and at 72 hours from C3 KO mice that were
injected with either anti-GBM or control IgG. The mice were killed
with CO2, and kidneys were harvested and snap-frozen for later
histological analysis.
Measurement of creatinine and proteinuria
Urine albumin was quantiﬁed using rocket immunoelectrophoresis
as previously described.24 Urine creatinine was quantiﬁed with
creatinine strips for the Reﬂotron Plus system (Roche Diagnostics,
Risch-Rotkreuz, Switzerland). The degree of proteinuria was calcu-
lated as the UACR.
Properdin ELISA
A speciﬁc ELISA for mouse properdin was developed with mouse
anti-mouse properdin monoclonal antibody (clone 17-17) and
rabbit polyclonal antibody raised against recombinant mouse
properdin.46 The capture monoclonal antibody was coated at 2
mg/ml in 96-well ELISA plates (Nunc Maxisorp; Thermo Fisher
Scientiﬁc, Waltham, MA). Following coating, the wells were
blocked with 1% bovine serum albumin in phosphate buffered
saline (PBS). Normal mouse CD-1 serum, recombinant mouse
properdin, or properdin KO serum was serially diluted in PBS,1147
Figure 7 | Colocalization of neutrophil inﬁltration with properdin deposition in anti–glomerular basement membrane (GBM) antibody–
affected glomeruli. (a) The double staining of properdin and neutrophils (GR1) was performed 2 hours after anti-GBM IgG administration. GR1
was detected with Alexa-568–labeled secondary antibody (red) and properdin with tyramide-FITC ampliﬁcation (green). Deposition was
evaluated in wild-type (WT) mice injected with control antibody, WT mice injected with anti-GBM antibody, and properdin knockout (KO) mice
injected with anti-GBM antibody. (b) Based on the GR1 stain the neutrophils were quantiﬁed and calculated as inﬁltrating cells per glomeruli. Rb
IgG, rabbit anti-GBM IgG. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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serum albumin (phenacyl thiazolium bromide) and added to the
blocked wells. Captured properdin was detected using digoxigenin
(DIG)-labeled rabbit anti-human properdin (in house, Leiden
University Medical Center), anti-DIG-POD (11207733910, Roche
Diagnostics), followed by colorimetric quantiﬁcation with a
colorimetric substrate step with 3,3’,5,5’-tetramethylbenzidine for
15 to 30 minutes at room temperature and stopped with 50 ml 1M
H2SO4 and read at 450 nm with a Bio-Rad 550 instrument (Bio-
Rad, Hercules, CA).
Complement activation fragments and functional
complement analysis
Measurement of functional mouse complement pathway activities
was performed with an ELISA-based system as described previ-
ously.39,45 In brief, human IgM-coated plates were used for CP,
Mannan-coated plates for LP, and LPS-coated plates for AP ELISA.
For CP and LP assessment plasma samples were diluted in MgCl2-
and CaCl2-supplemented Veronal buffered saline, and for AP sam-
ples Veronal buffer supplemented with MgCl2 and Ca
2þ-chelating
EGTA. Complement activity at the level of C3 was determined with
biotinylated rat anti-mouse C3b-C3c-iC3b monoclonal antibody
clone 2/1147 (HM1065; Hycult Biotech, Uden, Netherlands) and
Streptavidin-HRP conjugate (Hycult Biotech).1148Determination of activated mouse C3, MPO, and SAP
Commercial assays were used to measure SAP (HK215, Hycult
Biotech) and MPO (HK210, Hycult Biotech) according to manu-
facturer’s speciﬁcations. The C3b/C3c/iC3b quantiﬁcation was per-
formed as described previously.45
Histological analysis
Kidneys were sectioned into 4-mm slices using a cryostat, ﬁxed by 10-
minute incubation in acetone, and washed with PBS 3 times 5 mi-
nutes after each step, and all antibodies were diluted in 1% bovine
serum albumin and PBS.
Mouse properdin, C6, and C9 were detected using tyramide-
ﬂuorescein isothiocyanate (FITC) ampliﬁcation–based staining.
The slides were ﬁrst treated with 45-minute room temperature in-
cubation in PBS buffer containing 0.6% H2O2 (1.07209.0250; Merck
KGaA, Darmstadt, Germany) and 0.2% NaN3 (1.06688.0100, Merck)
diluted in PBS.
Properdin was detected with 1 mg/ml diluted rabbit anti-mouse
properdin-DIG described for the properdin ELISA (in house, Lei-
den University Medical Center), whereas mouse C6 and C9 were
detected with 1 mg/ml rabbit anti-mouse recombinant C6-DIG and
C9-DIG described previously.45 For both components, the detection
was followed with overnight incubation of the slides with 1/750
diluted sheep anti-DIG-POD (Roche Diagnostics). Finally, the slidesKidney International (2018) 94, 1141–1150
J O’Flynn et al.: Properdin binding in vivo can occur independently of C3 bas i c re sea r chwere incubated 20 minutes with 1/500 diluted tyramide-FITC
(T9034-4, Sigma-Aldrich) in tyramide buffer (NENTM, Life Sci-
ence Products, Chestertown, MD) with 0.01% H2O2 (Merck).
Mouse GR1 was detected with 1/400 diluted rat anti-mouse GR1
(a kind gift from Georg Kraal, VU University Medical Center,
Amsterdam, Netherlands) and 1/750 diluted goat anti-rat-Alexa 568
(A11011; Molecular Probes, Eugene, OR). Deposition of rabbit IgG
to mouse glomeruli was detected with 1/400 diluted goat anti-rabbit
IgG-Alexa 488 (A11008, Molecular Probes) or 1/400 diluted goat
anti-rabbit IgG-Alexa568 (ab175471; Abcam, Cambridge, UK).
Mouse C3 was detected with 1/1000 rat anti-mouse C3 (CL75603AP;
Cedarlane, Burlington, Canada), and 1/750 diluted goat anti-rat
Alexa 568 (A11011, Molecular Probes). Where applicable, nuclear
stains were performed with 1/10000 diluted Hoechst (H3569, Invi-
trogen, Carlsbad, CA) according to the manufacturer’s instructions.
Fluorescence microscopy was performed with a Zeiss Axio Scope A1
with an EX-plan Neoﬂuar 40x lens and captured with Axiocam
MRC5 (Carl Zeiss, Dublin, CA).
Speciﬁcity of the staining was conﬁrmed with renal tissue har-
vested 72 hours after injection of antibody. Rabbit IgG and C9 stain
speciﬁcity was controlled with mice injected with control rabbit IgG.
Properdin and C3 staining speciﬁcity was tested with properdin KO
and C3 KO mice injected with anti-GBM antibody. In all cases the
staining was free of nonspeciﬁc signal within the glomeruli, as
assessed by isotype controls.
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Netherlands).SUPPLEMENTARY MATERIAL
Table S1. Analysis of proteinuria and impact of gender to renal injury.
Table depicts the urinary albumin-creatinine ratio (UACR), urinary
albumin (mg/ml) and creatinine (mmol/l). The 24-hour urine was
collected between 72 to 96 hours in individual metabolic cages from
wild-type C57bl/6 (WT), properdin (fP) knockout (KO), and C3 KO
mice. Values are depicted as mean  SD.
Figure S1. Speciﬁcity of renal histology stains. (A) The speciﬁcity of
properdin (fP) and C3 stains were assessed with fP knockout (KO) and
C3 KO mice, respectively, and compared against wild-type (WT) mice.
The mice were injected with 0.5 mg rabbit (Rb) IgG anti–glomerular
basement membrane (GBM) antibody, and tissues were harvested at
72 hours. (B) Speciﬁcity of Rb IgG, C9, and GR1 stains were evaluated
against tissues collected from WT mice injected with either 0.5 mg
nonspeciﬁc Rb IgG or 0.5 mg Rb IgG anti-GBM. Mouse C9 assessment
was performed on tissues collected at 96 hours after injection,
whereas GR1 and Rb IgG were assessed with tissues collected at 2
hours after injection.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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